https://www.biopharmawatch.com/news/ICCM/icecure-new-patent-china-cryogenic-system BiopharmaWatch en 2026-11-09T13:25:00.000Z IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio https://www.biopharmawatch.com/news/EVMN/evommune-present-upcoming-investor-conferences BiopharmaWatch en 2026-11-09T13:05:00.000Z Evommune to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/XNCR/xencor-plamotamab-data-acr-convergence-2026 BiopharmaWatch en 2026-11-09T13:01:00.000Z Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657 https://www.biopharmawatch.com/news/QTRX/quanterix-q3-2026-financial-results BiopharmaWatch en 2026-11-09T13:00:00.000Z Quanterix Releases Financial Results for the Third Quarter of 2026 https://www.biopharmawatch.com/news/ARDT/ardent-health-ubs-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-09T13:00:00.000Z Ardent Health to Participate in the UBS Global Healthcare Conference https://www.biopharmawatch.com/news/TWST/twist-bioscience-present-upcoming-investor-conferences BiopharmaWatch en 2026-11-09T13:00:00.000Z Twist Bioscience to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-q3-2026-results BiopharmaWatch en 2026-11-09T13:00:00.000Z Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/DCTH/delcath-systems-q3-2026-results BiopharmaWatch en 2026-11-09T13:00:00.000Z Delcath Systems Reports Third Quarter 2026 Results and Business Highlights https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-scientific-advisory-board-formation BiopharmaWatch en 2026-11-09T13:00:00.000Z Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-11-09T13:00:00.000Z Edgewise Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-09T13:00:00.000Z Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/PLUR/pluri-iso-certifications-commercial-expansion BiopharmaWatch en 2026-11-09T13:00:00.000Z Pluri Adds ISO 9001 and ISO 13485 Certifications to Support PluriCDMO Commercial Expansion https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-warrant-purchase-results BiopharmaWatch en 2026-11-09T13:00:00.000Z Jasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants https://www.biopharmawatch.com/news/AMRN/amarin-new-data-lipoprotein-a-aha-2026 BiopharmaWatch en 2026-11-09T13:00:00.000Z Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026 https://www.biopharmawatch.com/news/HUMA/humacyte-first-in-human-coronary-bypass-study BiopharmaWatch en 2026-11-09T13:00:00.000Z Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/ONMD/onemednet-partners-ai-analytics-patient-journey BiopharmaWatch en 2026-11-09T13:00:00.000Z OneMedNet Partners to Combine First-Party Multimodal Clinical Data with Comprehensive Patient-Journey AI Analytics, Expanding Commercial Reach Through 13th Channel Partnership https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-rebrands-achieverx-quit-company BiopharmaWatch en 2026-11-09T13:00:00.000Z Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT https://www.biopharmawatch.com/news/MREO/mereo-biopharma-reports-q3-2026-results BiopharmaWatch en 2026-11-09T13:00:00.000Z Mereo BioPharma Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-trial-biomarker-data BiopharmaWatch en 2026-11-09T13:00:00.000Z BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-investor-conferences-2026 BiopharmaWatch en 2026-11-09T13:00:00.000Z Tectonic Therapeutic to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MNPR/monopar-data-wilson-disease-alxn1840-aasld-2026 BiopharmaWatch en 2026-11-09T13:00:00.000Z Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026 https://www.biopharmawatch.com/news/ADRX/adarx-pharmaceuticals-presentation-ubs-biopharma-conference BiopharmaWatch en 2026-11-09T13:00:00.000Z ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference https://www.biopharmawatch.com/news/AEON/aeon-biopharma-ind-abp-450-study BiopharmaWatch en 2026-11-09T13:00:00.000Z AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450 https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-phase-1-resolution-study BiopharmaWatch en 2026-11-09T13:00:00.000Z Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease https://www.biopharmawatch.com/news/EVAX/evaxion-amendment-registration-statement-eib-debt-settlement BiopharmaWatch en 2026-11-09T13:00:00.000Z Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement https://www.biopharmawatch.com/news/PROF/profound-medical-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-09T12:45:00.000Z Profound Medical to Participate in the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/MDCX/medicus-pharma-cd228v-development-strategy BiopharmaWatch en 2026-11-09T12:30:00.000Z Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-09T12:30:00.000Z AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights https://www.biopharmawatch.com/news/IBRX/immunitybio-reports-label-expansion-global-approval BiopharmaWatch en 2026-11-09T12:30:00.000Z ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million https://www.biopharmawatch.com/news/NGNE/neurogene-reports-q3-2026-results BiopharmaWatch en 2026-11-09T12:30:00.000Z Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-09T12:30:00.000Z ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-presentation-jefferies-conference-london BiopharmaWatch en 2026-11-09T12:30:00.000Z Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/CRVO/cervomed-third-quarter-2026-results BiopharmaWatch en 2026-11-09T12:30:00.000Z CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/BRVE/braveheart-bio-jefferies-conference-2026 BiopharmaWatch en 2026-11-09T12:30:00.000Z Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-09T12:30:00.000Z Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CYTK/cytokinetics-aficamten-hcms-2026-data BiopharmaWatch en 2026-11-09T12:30:00.000Z Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/BBIO/bridgebio-participate-november-december-investor-conferences BiopharmaWatch en 2026-11-09T12:30:00.000Z BridgeBio to Participate in November and December Investor Conferences https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-2026-jefferies-conference BiopharmaWatch en 2026-11-09T12:30:00.000Z Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/IMRX/immuneering-appoints-grant-bogle-board-directors BiopharmaWatch en 2026-11-09T12:30:00.000Z Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261109 BiopharmaWatch en 2026-11-09T12:29:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-09T12:22:00.000Z Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-obesityweek-2026-presentations BiopharmaWatch en 2026-11-09T12:05:00.000Z Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026 https://www.biopharmawatch.com/news/NRXS/neuraxis-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-09T12:05:00.000Z NeurAxis Reports Record Third Quarter 2026 Financial Results Driven by 150% Year Over Year Revenue Growth https://www.biopharmawatch.com/news/KIDS/orthopediatrics-launches-verteglide-spinal-growth-system BiopharmaWatch en 2026-11-09T12:05:00.000Z OrthoPediatrics Announces Full Commercial Launch of VerteGlide® Spinal Growth Guidance System https://www.biopharmawatch.com/news/KMDA/kamada-reports-record-high-financial-results-2026 BiopharmaWatch en 2026-11-09T12:02:00.000Z Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027 https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-announces-new-employee-inducement-grants-20261109 BiopharmaWatch en 2026-11-09T12:01:00.000Z Definium Therapeutics Announces New Employee Inducement Grants https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-positive-vrdn-008-phase-1-results BiopharmaWatch en 2026-11-09T12:01:00.000Z Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing https://www.biopharmawatch.com/news/ZURA/zura-bio-phase-2-tibushield-study-update BiopharmaWatch en 2026-11-09T12:00:00.000Z Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa https://www.biopharmawatch.com/news/IONS/ionis-reports-q3-2026-results BiopharmaWatch en 2026-11-09T12:00:00.000Z Ionis reports third quarter 2026 financial results and highlights progress on key programs https://www.biopharmawatch.com/news/UTHR/united-therapeutics-corporation-announces-participation-upcoming-investor-conferences BiopharmaWatch en 2026-11-09T12:00:00.000Z United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences https://www.biopharmawatch.com/news/PODD/insulet-give-yourself-freedom-diabetes-campaign BiopharmaWatch en 2026-11-09T12:00:00.000Z For World Diabetes Day, Insulet Launches “Give Yourself the Freedom to” Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-separation-crhx-101-adrenyx BiopharmaWatch en 2026-11-09T12:00:00.000Z Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences https://www.biopharmawatch.com/news/OFIX/orthofix-reports-q3-2026-results-guidance-revision BiopharmaWatch en 2026-11-09T12:00:00.000Z Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-reports-q3-2026-results BiopharmaWatch en 2026-11-09T12:00:00.000Z TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-corporate-updates-q3-2026 BiopharmaWatch en 2026-11-09T12:00:00.000Z Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IBRX/anktiva-bcg-approval-israel BiopharmaWatch en 2026-11-09T12:00:00.000Z ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ https://www.biopharmawatch.com/news/NVCR/novocure-fda-update-optune-mya-brain-metastases BiopharmaWatch en 2026-11-09T12:00:00.000Z Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/MANE/veradermics-vdphl01-phase-3-hair-loss-results BiopharmaWatch en 2026-11-09T12:00:00.000Z Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss https://www.biopharmawatch.com/news/FTH/faeth-positive-phase-2-results-piktor-trial BiopharmaWatch en 2026-11-09T12:00:00.000Z Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer https://www.biopharmawatch.com/news/CRMD/cormedix-acquires-heron-therapeutics-assets BiopharmaWatch en 2026-11-09T12:00:00.000Z CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care https://www.biopharmawatch.com/news/CGEN/compugen-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-09T12:00:00.000Z Compugen Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CTSO/cytosorbents-participate-jefferies-healthcare-conference-2026 BiopharmaWatch en 2026-11-09T12:00:00.000Z CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/MCTA/charming-medical-nasdaq-delisting-suspension BiopharmaWatch en 2026-11-09T12:00:00.000Z Charming Medical Limited Announces Nasdaq Delisting Determination and Suspension of Trading https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-bio-europe-2026-presentation BiopharmaWatch en 2026-11-09T12:00:00.000Z Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast https://www.biopharmawatch.com/news/ADAG/adagene-completes-enrollment-phase-2-trial-muzastotug BiopharmaWatch en 2026-11-09T12:00:00.000Z Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer https://www.biopharmawatch.com/news/KMDA/kamada-cash-dividend-announcement-2026 BiopharmaWatch en 2026-11-09T12:00:00.000Z Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-jefferies-conference-2026 BiopharmaWatch en 2026-11-09T12:00:00.000Z Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/ANVS/annovis-closes-21-million-public-offering BiopharmaWatch en 2026-11-09T12:00:00.000Z Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman https://www.biopharmawatch.com/news/INM/mentari-therapeutics-merger-inmed-pharmaceuticals-financing BiopharmaWatch en 2026-11-09T12:00:00.000Z Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-q3-2026-results BiopharmaWatch en 2026-11-09T12:00:00.000Z Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-secures-credit-facility-200-million BiopharmaWatch en 2026-11-09T12:00:00.000Z Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital https://www.biopharmawatch.com/news/AURA/aura-biosciences-q3-2026-results BiopharmaWatch en 2026-11-09T12:00:00.000Z Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-investor-conferences BiopharmaWatch en 2026-11-09T12:00:00.000Z NovaBridge Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-q3-2026-call BiopharmaWatch en 2026-11-09T12:00:00.000Z American Shared Hospital Services Announces Third Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-q3-2026-update BiopharmaWatch en 2026-11-09T12:00:00.000Z Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-q2-2026-business-update BiopharmaWatch en 2026-11-09T12:00:00.000Z Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update https://www.biopharmawatch.com/news/NKTX/nkarta-nkx019-clinical-data-acr-convergence BiopharmaWatch en 2026-11-09T12:00:00.000Z Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence https://www.biopharmawatch.com/news/EDIT/editas-medicine-q3-2026-results-business-updates BiopharmaWatch en 2026-11-09T12:00:00.000Z Editas Medicine Announces Third Quarter 2026 Results and Business Updates https://www.biopharmawatch.com/news/GLUE/monte-rosa-mrt-8102-gout-acr-convergence-2026 BiopharmaWatch en 2026-11-09T12:00:00.000Z Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-solara-trial-sutacimig-glanzmann-thrombasthenia BiopharmaWatch en 2026-11-09T12:00:00.000Z Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia https://www.biopharmawatch.com/news/SLXN/silexion-reverse-share-split-november-2026 BiopharmaWatch en 2026-11-09T12:00:00.000Z Silexion Therapeutics Announces 1-for-24 Reverse Share Split https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-09T12:00:00.000Z Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/IMVT/immunovant-provides-corporate-updates-reports-financial-results-quarter-ended-september BiopharmaWatch en 2026-11-09T12:00:00.000Z Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/CANF/can-fite-ten-year-survival-advanced-liver-cancer BiopharmaWatch en 2026-11-09T12:00:00.000Z Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study https://www.biopharmawatch.com/news/GTBP/gt-biopharma-oral-presentation-sitc-2026-annual-meeting BiopharmaWatch en 2026-11-09T12:00:00.000Z GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/IMCR/immunocore-investor-conferences-november-2026 BiopharmaWatch en 2026-11-09T12:00:00.000Z Immunocore to present at upcoming investor conferences https://www.biopharmawatch.com/news/LFST/lifestance-health-group-announces-launch-secondary-public-offering-20261109 BiopharmaWatch en 2026-11-09T11:54:00.000Z LifeStance Health Group Announces Launch of Secondary Public Offering https://www.biopharmawatch.com/news/PLX/prx-115-phase-2-release-study-gout BiopharmaWatch en 2026-11-09T11:45:00.000Z Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-09T11:35:00.000Z Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress https://www.biopharmawatch.com/news/IBRX/immunitybio-anktiva-bcg-quilt-2-005-trial-results BiopharmaWatch en 2026-11-09T11:30:00.000Z ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial https://www.biopharmawatch.com/news/CMPS/compass-pathways-psilocybin-nda-fda BiopharmaWatch en 2026-11-09T11:30:00.000Z Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-acquires-abo-801-private-placement BiopharmaWatch en 2026-11-09T11:30:00.000Z Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement https://www.biopharmawatch.com/news/CRL/charles-river-acquires-frontage-bioanalysis-dmpk BiopharmaWatch en 2026-11-09T11:10:00.000Z Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses https://www.biopharmawatch.com/news/NHC/national-healthcare-properties-board-appointments BiopharmaWatch en 2026-11-09T11:00:00.000Z National Healthcare Properties Announces Appointments of Jeff Olson and Craig Smith to the Board of Directors https://www.biopharmawatch.com/news/EDSA/edesa-kyorin-agreement-paridiprubart-development-japan BiopharmaWatch en 2026-11-09T11:00:00.000Z Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan https://www.biopharmawatch.com/news/BDSX/biodesix-mrd-strategy-amp-2026 BiopharmaWatch en 2026-11-09T11:00:00.000Z Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting https://www.biopharmawatch.com/news/NUTX/nutex-health-houston-top-workplace-2026 BiopharmaWatch en 2026-11-09T10:30:00.000Z Nutex Health Named a 2026 Houston Top Workplace by Houston Chronicle https://www.biopharmawatch.com/news/CTNM/qureight-fibrosis-imaging-biomarker-contineum-therapeutics BiopharmaWatch en 2026-11-09T09:35:00.000Z Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-11-09 BiopharmaWatch en 2026-11-09T07:15:35.514Z selinexor and ruxolitinib for Myelofibrosis: Biotech Catalysts Nov 9, 2026 https://www.biopharmawatch.com/news/OCS/oculis-rd-day-late-stage-development-pipeline BiopharmaWatch en 2026-11-09T07:00:00.000Z Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline https://www.biopharmawatch.com/news/ARGX/argenx-acquire-unnatural-products-peptide-discovery BiopharmaWatch en 2026-11-09T06:00:00.000Z argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities https://www.biopharmawatch.com/news/BIIB/dapirolizumab-pegol-acr-2026-sle-response-rates BiopharmaWatch en 2026-11-09T06:00:00.000Z ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure https://www.biopharmawatch.com/news/ARGX/argenx-acquires-unnatural-products-1-15-billion BiopharmaWatch en 2026-11-09T06:00:00.000Z Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines https://www.biopharmawatch.com/news/VALN/valneva-positive-phase-2-results-shigella-vaccine-s4v2 BiopharmaWatch en 2026-11-09T06:00:00.000Z Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2 https://www.biopharmawatch.com/news/MANE/veradermics-hold-conference-call-discuss-12-month-long-term-results BiopharmaWatch en 2026-11-08T23:00:00.000Z Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss https://www.biopharmawatch.com/news/IMMP/imp761-phase-i-study-results-acr-convergence-2026 BiopharmaWatch en 2026-11-08T22:34:00.000Z IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses https://www.biopharmawatch.com/news/VIR/vir-biotechnology-phase-2-solstice-data-elebsiran-tobevibart BiopharmaWatch en 2026-11-08T21:45:00.000Z Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data https://www.biopharmawatch.com/news/MLYS/lorundrostat-transform-htn-trial-results-aha-2026 BiopharmaWatch en 2026-11-08T21:35:00.000Z Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026 https://www.biopharmawatch.com/news/VIR/vir-biotechnology-eclipse-1-trial-results BiopharmaWatch en 2026-11-08T21:15:00.000Z Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta https://www.biopharmawatch.com/news/RDNT/radnet-third-quarter-results-2026 BiopharmaWatch en 2026-11-08T21:01:00.000Z RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges https://www.biopharmawatch.com/news/REGN/cid-eb-sirna-normalizes-liver-fat-masld-patients BiopharmaWatch en 2026-11-08T21:00:00.000Z CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD https://www.biopharmawatch.com/news/RCEL/avita-medical-host-investor-webinar-briefing-20261108 BiopharmaWatch en 2026-11-08T20:30:00.000Z AVITA Medical to Host Investor Webinar Briefing https://www.biopharmawatch.com/news/JNJ/jnj-reports-73-percent-psa-response-rate BiopharmaWatch en 2026-11-08T16:00:00.000Z Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer https://www.biopharmawatch.com/news/CGEM/velinotamig-complete-renal-responses-sle-acr-2026 BiopharmaWatch en 2026-11-08T15:30:11.000Z Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-update-zugocabtagene-geleucel BiopharmaWatch en 2026-11-08T15:30:00.000Z CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases https://www.biopharmawatch.com/news/CABA/cabaletta-bio-resec-cel-phase-1-2-data-acr-2026 BiopharmaWatch en 2026-11-08T15:00:00.000Z Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-plozasiran-data-presentation BiopharmaWatch en 2026-11-07T21:15:00.000Z Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates https://www.biopharmawatch.com/news/JNJ/j-j-icotyde-improves-psoriatic-arthritis-activity BiopharmaWatch en 2026-11-07T15:03:00.000Z Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide https://www.biopharmawatch.com/news/JNJ/jnj-nipocalimab-phase-2-sjogrens-disease-data BiopharmaWatch en 2026-11-07T15:03:00.000Z Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients https://www.biopharmawatch.com/news/ARGX/argenx-phase-3-alkivia-data-acr-convergence-2026 BiopharmaWatch en 2026-11-07T15:01:00.000Z argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis https://www.biopharmawatch.com/news/OGN/real-world-evidence-hadlima-acr-meeting BiopharmaWatch en 2026-11-07T15:00:00.000Z New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System